Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes year-end report 2025

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the year-end report for the fourth quarter and full year 2025.

"Strong growth, scalability and clear progress." Torbjörn Sköld, CEO

OCTOBER - DECEMBER 2025

• Net sales increased by 22 percent (36 percent at constant exchange rates) and amounted to SEK 312.5 million (257.0).
• The US segment reported a sales growth of 24 percent (40 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales growth of 13 percent (18 percent at constant exchange rates).
• The gross margin amounted to 92.5 percent (92.6).
• The adjusted operating result amounted to SEK 81.3 million (78.0). The reported operating result amounted to SEK 81.8 million (64.2).
• Earnings per share before dilution were SEK 0.67 (0.82).
• Earnings per share after dilution were SEK 0.66 (0.81).

JANUARY - DECEMBER 2025

• Net sales increased by 31 percent (40 percent at constant exchange rates) and amounted to SEK 1,174.7 million (898.7).
• The US segment reported a sales growth of 36 percent (46 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales growth of 11 percent (15 percent at constant exchange rates).
• The gross margin amounted to 92.6 percent (92.6).
• The adjusted operating result amounted to SEK 262.0 million (203.9). The reported operating result amounted to SEK 231.7 million (166.1).
• Earnings per share before dilution were SEK 2.16 (2.04)
• Earnings per share after dilution were SEK 2.13 (2.01).

EVENTS DURING THE QUARTER

• In December, the Company announced a change in the regulatory process for its market application to the US Food and Drug Administration (FDA) for CERAMENT V for the indication of bone infection. As a consequence, the application is transferred from a 510(k) process to a De Novo process. All documentation and data was transferred and submitted during December.
• During the quarter, an annual reconciliation was made of the share swap that was entered into during the previous year. As a consequence of a lower share price than at the start of the agreement, a payment has been made of SEK 33.2 million to the Company's bank.
• During the quarter, in accordance with authorization from the Annual General Meeting 2025, the Board of Directors of BONESUPPORT utilized the authorization to enter into a share swap agreement with the Company's bank. The agreement amounted to SEK 16.2 million and its purpose is to secure the delivery of performance shares to the participants of the long term incentive programs that the Annual General Meeting has decided to implement.

EVENTS AFTER THE PERIOD

• Nothing to report.

For more information contact:

BONESUPPORT Holding AB
Torbjörn Sköld, CEO
[phone]

Håkan Johansson, CFO
[phone]
[e-mail]

Cord Communications
Charlotte Stjerngren
[phone]
[e-mail]
www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-24 08:00 CET.

About BONESUPPORT

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to 1,175 msek in 2025. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.